Articles tagged with Gene Editing
Scientists have developed a method to observe gene editing in real-time, enabling the investigation of CRISPR-Cas9's biological processes and potential applications for treating genetic diseases such as sickle cell anemia and cystic fibrosis.
A team of researchers discovered that a specific mutation in the telomere protein TPP1 causes an incurable premature aging disease called dyskeratosis congenita. The mutation compromises telomerase function, leading to stem cell division slowdowns and tissue breakdown. This breakthrough provides a potential drug target for the disease.
Researchers developed a novel gene editing strategy to correct thalassemia mutations in mice, alleviating symptoms and normalizing hemoglobin levels. The technique, which uses nanoparticles and synthetic DNA, has the potential to treat people with inherited blood disorders like sickle cell anemia.
A new gene-editing system successfully cured a genetic blood disorder in living mice, offering a minimally invasive treatment for beta thalassemia and sickle cell disease. The technology significantly decreases unwanted gene mutations and uses FDA-approved nanoparticles to deliver PNA molecules.
Researchers at St. Jude Children's Research Hospital have found a way to use CRISPR gene editing to help fix sickle cell disease and beta-thalassemia in blood cells isolated from patients. The study provides proof-of-principle for a new approach to treat common blood disorders by genome editing.
Researchers outline recent progress in clinical applications of retinal gene replacement therapy and preclinical advances in gene-specific therapy for photoreceptor diseases. Gene therapy strategies are being developed to treat a broader range of disorders affecting vision, providing new hope for individuals with eye diseases.
Promising results from clinical trials of globin gene transfer have eliminated the need for blood transfusions in some individuals with beta-thalassemias. Gene editing technologies hold promise to correct beta-globin deficiencies and reactivate fetal hemoglobin production, potentially leading to a cure for severe globin disorders.
The Hastings Center has launched a three-year project to examine the fundamental questions of using gene editing in humans, including its impact on human flourishing and core values. The project aims to develop new scholarship, equips journalists, and prepares teachers to engage with these issues.
Researchers suggest using CRISPR-Cas9 technology to introduce a male sex determining gene into female mosquito embryos, potentially reducing disease transmission. The goal is to create sterile or fertile males that outcompete females in the wild.
Researchers have developed a CRISPR-Cas9 gene editing system to treat Duchenne muscular dystrophy (DMD), a debilitating genetic disease. By deleting exon 23 and restoring dystrophin protein levels, the therapy improved muscle function in mice with DMD, including cardiac and pulmonary health.
Scientists have created RNA-based drugs that can temporarily activate and inactivate the CRISPR/Cas9 gene editing system, providing more precise control over gene expression. This breakthrough enables researchers to correct and inactivate genes with increased efficiency and potential selectivity.